

Cellular senescence: when bad things happen to good cells

Judith Campisi* and Fabrizio d'Adda di Fagagna†

Abstract | Cells continually experience stress and damage from exogenous and endogenous sources, and their responses range from complete recovery to cell death. Proliferating cells can initiate an additional response by adopting a state of permanent cell-cycle arrest that is termed cellular senescence. Understanding the causes and consequences of cellular senescence has provided novel insights into how cells react to stress, especially genotoxic stress, and how this cellular response can affect complex organismal processes such as the development of cancer and ageing.

Renewable tissue

A tissue in which cell proliferation is important for tissue repair or regeneration. Renewable tissues typically contain, but sometimes recruit, mitotic cells upon injury or cell loss.

Cellular senescence was formally described more than four decades ago when Hayflick and colleagues showed that normal cells had a limited ability to proliferate in culture¹ (see BOX 1 for descriptions of different types of senescence). These classic experiments showed that human fibroblasts initially underwent robust cell division in culture. However, gradually — over many cell doublings — cell proliferation (used here interchangeably with cell growth) declined. Eventually, all cells in the culture lost the ability to divide. The non-dividing cells remained viable for many weeks, but failed to grow despite the presence of ample space, nutrients and growth factors in the medium.

Soon after this discovery, the finding that normal cells do not indefinitely proliferate spawned two important hypotheses. At the time, both were highly speculative and seemingly contradictory. The first hypothesis stemmed from the fact that many cancer cells proliferate indefinitely in culture. Cellular senescence was proposed to be an anti-cancer or tumour-suppressive mechanism. In this context, the senescence response was considered beneficial because it protected organisms from cancer, a major life-threatening disease. The second hypothesis stemmed from the fact that tissue regeneration and repair deteriorate with age. Cellular senescence was proposed to recapitulate the ageing, or loss of regenerative capacity, of cells *in vivo*. In this context, cellular senescence was considered deleterious because it contributed to decrements in tissue renewal and function. For many years, these hypotheses were pursued more or less independently. However, as an understanding of the senescence response grew, these hypotheses coalesced, bringing new insights to the fields of cancer and ageing. Here, we review recent progress in understanding the causes

of cellular senescence, and the evidence that it is important for suppressing cancer and a possible contributor to ageing.

Senescence in an evolutionary context

To understand how cellular senescence can be both beneficial and detrimental, and the origins of its regulation, it is important to understand the nature of cancer and the evolutionary theory of ageing. Cancer is often fatal and therefore poses a major challenge to the longevity of organisms with renewable tissues. Tissue renewal is essential for the viability of complex organisms such as mammals. However, cell proliferation is essential for tumorigenesis, and renewable tissues are at risk of developing cancer². Moreover, cancer initiates and, to a large extent, progresses owing to somatic mutations³, and proliferating cells acquire mutations more readily than non-dividing cells⁴. The danger that cancer posed to longevity was mitigated by the evolution of tumour-suppressor mechanisms. One such mechanism was cellular senescence, which stops incipient cancer cells from proliferating^{5–7}.

The environment in which cellular senescence evolved was replete with extrinsic hazards such as infection, predation and starvation. Hence, organismal lifespans were relatively short owing to death from these hazards. Therefore, tumour-suppressor mechanisms needed to be effective for only a relatively short interval (a few decades for humans, several months for mice). Should such mechanisms be deleterious later (for example, if the regenerative capacity were to decline or if dysfunctional senescent cells were to accumulate), there would be little selective pressure to eliminate the harmful effects. Therefore, some tumour-suppressor mechanisms can be both beneficial

*Life Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, California 94720, USA; and Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, California 94945, USA.
†IFOM Foundation, FIRC Institute of Molecular Oncology, Via Adamello 16, 20139 Milan, Italy.
e-mails: jcampisi@lbl.gov; fabrizio.dadda@ifom-ieo-campus.it
doi:10.1038/nrm2233
Published online
1 August 2007

Box 1 | A hitchhiker's guide to senescence nomenclature

- Senescence derives from *senex*, a Latin word meaning old man or old age. In organismal biology, senescence describes deteriorative processes that follow development and maturation, and the term is used interchangeably with ageing.
- The term senescence was applied to cells that ceased to divide in culture¹, based on the speculation that their behaviour recapitulated organismal ageing. Consequently, cellular senescence is sometimes termed cellular ageing or replicative senescence.
- Cells that are not senescent are termed pre-senescent, early passage, proliferating or, sometimes, young.
- Telomere shortening provided the first molecular explanation for why many cells cease to divide in culture^{61,68}. Dysfunctional telomeres trigger senescence through the p53 pathway. This response is often termed telomere-initiated cellular senescence.
- Some cells undergo replicative senescence independently of telomere shortening^{16,53,101}. This senescence is due to stress, the nature of which is poorly understood. It increases p16 expression and engages the p16–retinoblastoma protein (pRB) pathway. This response is termed stress-induced or premature senescence, stasis or M0 (mortality phase 0).
- Certain mitogenic oncogenes or the loss of anti-mitogenic tumour-suppressor genes induce senescence in normal cells^{83,92,93,95}. This is known as oncogene-induced senescence.
- Cells that do not divide indefinitely are said to have a finite or limited replicative (or proliferative) lifespan and are (replicatively) mortal. Cells that proliferate indefinitely are termed (replicatively) immortal.
- Immortal cells are not necessarily transformed (tumorigenic) cells. Although historically the terms immortalization and transformation have been used interchangeably, the replicative lifespan of cells can be expanded indefinitely by the expression of telomerase without the phenotypic changes that are associated with malignant transformation¹³⁸.
- Telomere-initiated senescence is sometimes termed M1 (mortality phase 1)¹⁵³. Some cells (for example, fibroblasts) undergo telomere-initiated senescence with few signs of genomic instability. Other cells (for example, some epithelial cells) arrest with obvious signs of genomic instability and are termed agonescent¹⁵⁴.
- Human cells that escape telomere-initiated senescence (M1) or agonescence owing to the loss of p53 function can proliferate until they enter a state that is termed crisis, mitotic catastrophe or M2 (mortality phase 2)¹⁵³. This state is characterized by extensive genomic instability and cell death.

Antagonistic pleiotropy

The hypothesis that genes or processes that were selected to benefit the health and fitness of young organisms can have unselected deleterious effects that manifest in older organisms and thereby contribute to ageing.

Mitotic cell

A cell that has the ability to proliferate. *In vivo*, mitotic cells often exist in a reversible growth-arrested state that is termed quiescence or G0 phase, but such cells can be stimulated to proliferate in response to appropriate physiological signals.

Post-mitotic cell

A cell that has permanently lost the ability to proliferate, usually due to differentiation.

and deleterious, depending on the age of the organism⁸. This concept — that a process can be beneficial to young organisms but harmful to old organisms — is the essence of antagonistic pleiotropy, an important evolutionary theory of ageing⁹. There is now substantial evidence that cellular senescence is indeed a potent tumour-suppressor mechanism^{6,7,10,11}, and there is also mounting — but still largely circumstantial — evidence that cellular senescence promotes ageing^{12–14}.

Characteristics of senescent cells

Complex organisms such as mammals contain both mitotic cells and post-mitotic cells (BOX 2). Cellular senescence is confined to mitotic cells, from which cancer can arise. Although mitotic cells can proliferate, they can also spend long intervals in a reversibly arrested state termed quiescence or G0. Quiescent cells resume proliferation in response to appropriate signals, including the need for tissue repair or regeneration. By contrast, post-mitotic cells permanently lose the ability to divide owing to differentiation.

Mitotic cells can senesce when they encounter potentially oncogenic events (discussed below). When this occurs, the cells cease proliferation (known as growth arrest), in essence irreversibly. They often become resistant to cell-death signals (apoptosis resistance) and they acquire widespread changes in gene expression (altered gene expression). Together, these features comprise the senescent phenotype (FIG. 1).

Growth arrest. The hallmark of cellular senescence is an inability to progress through the cell cycle. Senescent cells arrest growth, usually with a DNA content that is typical of G1 phase, yet they remain metabolically active^{15–18}. Once arrested, they fail to initiate DNA replication despite adequate growth conditions. This replication failure is primarily caused by the expression of dominant cell-cycle inhibitors (see below). In contrast to quiescence, the senescence growth arrest is essentially permanent (in the absence of experimental manipulation) because senescent cells cannot be stimulated to proliferate by known physiological stimuli.

The features and stringency of the senescence growth arrest vary depending on the species and the genetic background of the cell. For example, most mouse fibroblasts senesce with a G1 DNA content, although a defect in the stress-signalling kinase MKK7 primarily induces a G2–M arrest¹⁹. Likewise, some oncogenes (see below) cause a fraction of cells to senesce with a DNA content that is typical of G2 phase^{20–22}. Furthermore, tumour cells can senesce with G2- or S-phase DNA contents. Although tumour cells usually proliferate indefinitely in culture, some of them retain the ability to undergo a senescence-like arrest, especially in response to certain anti-cancer therapies²³. Finally, human and rodent cells differ strikingly in the stringency of the senescence growth arrest²⁴. Like human cells, many mouse and rat cells have a finite proliferative capacity in culture, although, as discussed below, the mechanisms that limit this proliferation probably differ. However, rodent cell cultures frequently acquire spontaneous variants that can divide indefinitely. Such variants are exceedingly rare in human cultures.

Apoptosis resistance. Apoptosis entails the controlled destruction of cellular constituents and their ultimate engulfment by other cells²⁵. Like senescence, apoptosis is an extreme response to cellular stress and is an important tumour-suppressive mechanism²⁶. But, whereas senescence prevents the growth of damaged or stressed cells, apoptosis quickly eliminates them.

Many (but not all) cell types acquire resistance to certain apoptotic signals when they become senescent. For example, senescent human fibroblasts resist ceramide-induced apoptosis but endothelial cells do not²⁷. Senescent human fibroblasts also resist apoptosis caused by growth-factor deprivation and oxidative stress, but do not resist apoptosis caused by engagement of the Fas death receptor^{28,29}. Resistance to apoptosis might partly explain why senescent cells are so stable in culture. This attribute might also explain why the number of senescent cells increases with age, although, as discussed below, several factors probably contribute to this phenomenon.

Box 2 | Mitotic and post-mitotic cells

Mitotic cells are capable of proliferation, and they include the epithelial, stromal (fibroblastic) and vascular (endothelial) cells that comprise the major renewable tissues and organs such as the skin, intestines, liver, kidney and so on. They also comprise major components of the haematopoietic system, and cells such as the glia, which support the survival and function of non-dividing neurons. Mitotic cells also include the undifferentiated stem and progenitor cells that provide many of these tissues with the differentiated cells that are required for their function. Mitotic cells are susceptible to malignant transformation (that is, transformation into a cancer cell). They are also susceptible to undergoing cellular senescence when challenged by stimuli that have the potential to cause cancer.

Post-mitotic cells are incapable of proliferation. They include the differentiated neurons and muscle cells that comprise the brain, heart and skeletal muscle. Recent findings suggest that tissues that are composed mainly of post-mitotic cells can undergo limited repair and regeneration; however, this regeneration is not due to the proliferation of post-mitotic cells, but rather to the recruitment of mitotic stem cells or their progeny (progenitor cells)^{155–157}. Because they have already lost the ability to proliferate, post-mitotic cells do not undergo cellular senescence as currently defined.

Post-mitotic and senescent cells are irreversibly blocked from re-entering the cell cycle. The mechanisms that prevent these cells from undergoing cell division are incompletely understood, but probably share some common effectors.

Quiescence

A reversible non-dividing state from which cells can be stimulated to proliferate in response to physiological signals.

Senescent phenotype

The combination of changes in cell behaviour, structure and function that occur upon cellular senescence. For most cell types, these changes include an essentially irreversible growth arrest, resistance to apoptosis and many alterations in gene expression.

Oncogene

A gene that contributes to the malignant transformation of cells. Oncogenes can be cellular or viral in origin. Cellular oncogenes are usually mutant or overexpressed forms of normal cellular genes. Viral oncogenes can also originate from cellular genes, acquiring mutations during viral capture, but they can also be distinctly viral in origin.

Chromatin

The DNA and complex of associated proteins that determine the accessibility of large DNA regions to the transcription machinery and other large protein complexes.

It is not clear what determines whether cells undergo senescence or apoptosis. One determinant is cell type; for example, damaged fibroblasts and epithelial cells tend to senesce, whereas damaged lymphocytes tend to undergo apoptosis. The nature and intensity of the damage or stress may also be important^{30,31}. Most cells are capable of both responses. Moreover, manipulation of pro- and anti-apoptotic proteins can cause cells that are destined to die by apoptosis to senesce and, conversely, cause cells that are destined to senesce to undergo apoptosis^{30–32}. The senescence and apoptosis regulatory systems therefore communicate — probably through their common regulator, the p53 tumour suppressor protein³¹. The mechanisms by which senescent cells resist apoptosis are poorly understood. In some cells, resistance might be due to expression changes in proteins that inhibit, promote or implement apoptotic cell death^{33,34}. In others, p53 might preferentially transactivate genes that arrest proliferation, rather than those that facilitate apoptosis³⁵.

Altered gene expression. Senescent cells show striking changes in gene expression, including changes in known cell-cycle inhibitors or activators^{35–41}. Two cell-cycle inhibitors that are often expressed by senescent cells are the cyclin-dependent kinase inhibitors (CDKIs) p21 (also termed CDKN1a, p21Cip1, Waf1 or SDI1) and p16 (also termed CDKN2a or p16INK4a)^{6,7}. These CDKIs are components of tumour-suppressor pathways that are governed by the p53 and retinoblastoma (pRB) proteins, respectively. p53 and pRB are transcriptional regulators, and the pathways they govern are frequently disrupted in cancer⁴². Both pathways can establish and maintain the growth arrest that is typical of senescence. p21 is induced directly by p53 (REFS 35,43) but the mechanisms that induce p16, a tumour suppressor in its own right, are incompletely understood⁴⁴. Ultimately, p21 and p16 maintain pRB in a hypophosphorylated and active state but, as discussed below, their activities are not equivalent.

Senescent cells also repress genes that encode proteins that stimulate or facilitate cell-cycle progression (for example, replication-dependent histones, c-FOS, cyclin A, cyclin B and PCNA (proliferating cell nuclear antigen))^{45–48}. Some of these genes are repressed because E2F, the transcription factor that induces them, is inactivated by pRB. In some senescent cells, E2F target genes are silenced by a pRB-dependent reorganization of chromatin into discrete foci that are termed senescence-associated heterochromatin foci (SAHFs)⁴⁵.

Interestingly, many changes in gene expression appear to be unrelated to the growth arrest. Many senescent cells overexpress genes that encode secreted proteins that can alter the tissue microenvironment^{36–41}. For example, senescent fibroblasts overexpress proteins that remodel the extracellular matrix or mediate local inflammation. As discussed below, these findings raise the possibility that as senescent cells increase with age, they might contribute to age-related decrements in tissue structure and function^{8,12}. The mechanisms that are responsible for the senescence-associated secretory phenotype are unknown.

Senescence markers. Several markers can identify senescent cells in culture and *in vivo*. However, no markers are exclusive to the senescent state. A poorly understood feature of these markers is that, aside from the decline in DNA replication, all of them require several days to develop.

An obvious marker for senescent cells is the lack of DNA replication, which is typically detected by the incorporation of 5-bromodeoxyuridine or ³H-thymidine, or by immunostaining for proteins such as PCNA and Ki-67. Of course, these markers do not distinguish between senescent cells and quiescent or differentiated post-mitotic cells. The first marker to be used for the more specific identification of senescent cells was the senescence-associated β -galactosidase (SA- β gal)⁴⁹. This marker is detectable by histochemical staining in most senescent cells. However, it is also induced by stresses such as prolonged confluence in culture. The SA- β gal probably derives from the lysosomal β -galactosidase and reflects the increased lysosomal biogenesis that commonly occurs in senescent cells⁵⁰. In addition, p16 — an important regulator of senescence — is now used to identify senescent cells⁵¹. p16 is expressed by many, but not all, senescent cells^{52,53} and it is also expressed by some tumour cells, especially those that have lost pRB function⁴⁴. Recently, three proteins were identified in a screen for genes that were expressed following oncogene-induced senescence, and the proteins were subsequently used to identify senescent cells: DEC1 (differentiated embryo-chondrocyte expressed-1), p15 (a CDKI) and DCR2 (decoy death receptor-2)⁵⁴. The specificity and significance of these proteins for senescent cells are not yet clear, but they are promising additional markers.

Some senescent cells can also be identified by the cytological markers of SAHFs⁴⁵ and senescence-associated DNA-damage foci (SDFs)^{16,20,55,56}. SAHFs are detected by the preferential binding of DNA dyes, such as




Figure 1 | The senescent phenotype induced by multiple stimuli. Mitotically competent cells respond to various stressors by undergoing cellular senescence. These stressors include dysfunctional telomeres, non-telomeric DNA damage, excessive mitogenic signals including those produced by oncogenes (which also cause DNA damage), non-genotoxic stress such as perturbations to chromatin organization and, probably, stresses with an as-yet-unknown etiology. The senescence response causes striking changes in cellular phenotype. These changes include an essentially permanent arrest of cell proliferation, development of resistance to apoptosis (in some cells), and an altered pattern of gene expression. The expression or appearance of senescence-associated markers such as senescence-associated β -galactosidase, p16, senescence-associated DNA-damage foci (SDFs) and senescence-associated heterochromatin foci (SAHF) are neither universal nor exclusive to the senescent state and therefore are not shown.

4',6-diamidino-2-phenylindole (DAPI), and the presence of certain heterochromatin-associated histone modifications (for example, H3 Lys9 methylation) and proteins (for example, heterochromatin protein-1 (HP1)). SAHFs also contain E2F target genes, which SAHFs are thought to silence. In mouse cells, pericentromeric chromatin also preferentially binds DAPI, contains modified histones and proteins found in SAHFs, and forms cytologically detectable foci. However, there is no evidence that these foci contain E2F target genes; indeed, they are also present in proliferating cells. Because pericentromeric foci are much more prominent in mouse cells than human cells^{57,58}, they can be mistaken for SAHFs. SDFs, by contrast, are present in senescent cells from mice and humans and contain proteins that are associated with DNA damage (for example, phosphorylated histone H2AX (γ -H2AX) and p53-binding protein-1 (53BP1)). As discussed below, these foci result from dysfunctional telomeres and other sources of DNA damage.

Causes of cellular senescence

What causes cells to senesce? The first clues came from understanding why normal human cells do not proliferate indefinitely in culture (BOX 1), but subsequent studies showed that senescence can be induced by many stimuli (FIG. 1).

Telomere-dependent senescence. Telomeres are stretches of repetitive DNA (5'-TTAGGG-3' in vertebrates) and associated proteins that cap the ends of linear chromosomes and protect them from degradation or fusion by DNA-repair processes⁵⁹. The precise telomeric structure is not known, but mammalian telomeres are thought to end in a large circular structure, termed a t-loop⁶⁰. Because standard DNA polymerases cannot completely replicate DNA ends — a phenomenon called the end-replication problem — cells lose 50–200 base pairs of telomeric DNA during each S phase⁶¹ (FIG. 2). Human telomeres range from a few kilobases to 10–15 kb in length, so many cell divisions are possible before the end-replication problem renders telomeres critically short and dysfunctional. Only one or a few such telomeres are sufficient to trigger senescence^{62,63}. The end-replication problem is a major (but not the sole) reason why normal cells do not proliferate indefinitely (BOX 1).

Dysfunctional telomeres trigger a classical DNA-damage response (DDR)^{16,55,56,64} (FIG. 3). The DDR enables cells to sense damaged DNA, particularly double-strand breaks (DSBs), and to respond by arresting cell-cycle progression and repairing the damage if possible. Although the severity of the damage is probably an important factor, little is known about how cells choose between transient DDR activation and the persistent DDR signalling that is evident in many senescent cells. Many proteins participate in the DDR, including protein kinases (for example, ataxia telangiectasia mutated (*ATM*) and checkpoint-2 (*CHK2*)), adaptor proteins (for example, 53BP1 and MDC1 (mediator of DNA damage checkpoint protein-1)) and chromatin modifiers (for example, γ -H2AX). Many of these proteins localize to the DNA-damage foci that are detected in senescent cells. In cells that senesce owing to dysfunctional telomeres, these foci also contain a subset of telomeres, suggesting that dysfunctional telomeres resemble DSBs.

The end-replication problem can be circumvented by telomerase. This enzyme contains a catalytic protein component (telomerase reverse transcriptase; TERT) and a template RNA component, and adds telomeric DNA repeats directly to chromosome ends⁶⁵. Most normal cells do not express TERT, or express it at levels that are too low to prevent telomere shortening^{66,67}. By contrast, germ-line cells and many cancer cells express TERT. Moreover, ectopic TERT expression in normal human cells simultaneously prevents telomere shortening and senescence caused by the end-replication problem⁶⁸. However, telomerase cannot prevent senescence caused by non-telomeric DNA damage or other senescence inducers⁶⁹.

This point is demonstrated by the behaviour of many mouse cells. In contrast to most human cells, cells from laboratory mice have long telomeres (>20 kb) and many express telomerase. Nonetheless, many mouse cells senesce after only a few doublings under standard culture conditions. This arrest is due to the supraphysiological oxygen level (20%) that is used in standard culture protocols. A 20% oxygen level, to which mouse cells are much more sensitive than human cells, causes severe DNA damage and, in the absence of efficient repair




Figure 2 | Telomere-dependent senescence. Telomeres are stretches of a repetitive DNA sequence and associated proteins (magenta) that are located at the termini of linear chromosomes (blue). The telomeric ends form a circular protective cap termed the t-loop, which may help to prevent the termini from triggering a full DNA-damage response (DDR). Telomere lengths are maintained by the enzyme telomerase, which is expressed by cells that comprise the germline as well as many cancer cells. Most normal somatic cells do not express this enzyme, or express it only transiently or at levels that are too low to prevent telomere shortening caused by the end-replication problem. In such cells, telomere lengths decline with each cell cycle. Eventually, one or a few telomeres become sufficiently short and malfunction, presumably owing to loss of the protective protein–DNA structure. Dysfunctional telomeres trigger a DDR, to which cells respond by undergoing senescence.

mechanisms, DSBs. Both the damage and replicative failure are mitigated by culturing mouse cells at a (lower) physiological oxygen level⁷⁰.

DNA-damage-initiated senescence. Severe DNA damage that occurs anywhere in the genome — especially damage that creates DSBs — causes many cell types to undergo senescence^{15,70}. In culture, such cells harbour SDFs for many weeks or longer (J.C. and F.d'A.d.F., unpublished observations). There is as yet no firm evidence that these persistent foci contain irreparable DSBs. Whatever their nature, they may provide constitutive signals to p53 to maintain the senescence growth arrest.

Both damage- and telomere-initiated senescence depend strongly on p53 and are usually accompanied by expression of p21 (REFS 15,16,55) (FIG. 4). However, in many cells, DNA damage and dysfunctional telomeres also induce p16, albeit with delayed kinetics. p16, then, provides a second barrier to prevent the growth of cells with severely damaged DNA or dysfunctional telomeres^{52,71,72}.

Many chemotherapeutic drugs cause severe DNA damage. As expected, such drugs induce senescence in normal cells. Surprisingly, they also induce senescence in some tumour cells, both in culture and *in vivo*⁷³. Tumour cells with wild-type, as opposed to mutant, p53 are more likely to senesce in response to chemotherapy, at

least in cell culture and cancer-prone mouse models^{74–76}, consistent with a pivotal role for p53 in damage-induced senescence. Of practical importance, DNA-damaging therapies are more likely to be efficacious in tumours that senesce, compared with those that do not^{73–76}.

Senescence caused by chromatin perturbation. The chromatin state determines the extent to which genes are active (euchromatin) or silent (heterochromatin), and depends mainly on histone modifications (for example, acetylation and methylation). Interestingly, chemical histone deacetylase inhibition (HDAi), which promotes euchromatin formation, induces senescence^{17,77}. The mechanism by which this occurs is poorly understood, and may differ depending on the species and cell type. For example, in human fibroblasts, HDAi sequentially induces p21 and p16 expression, and the senescence growth arrest critically depends on the presence of pRB. By contrast, in mouse fibroblasts, the p53 pathway is more important for the senescence response to HDAi (REF. 77). Because HDAi can induce ATM kinase activity⁷⁸, HDAi might cause senescence in some cells by initiating a p53-dependent DDR.

The finding that HDAi causes senescence appears to conflict with the role of heterochromatin and SAHF in establishing and maintaining the senescent growth arrest⁴⁵. Likewise, HDAi-induced senescence seems to be in conflict with the finding that downregulation of a histone acetyl transferase, which promotes heterochromatin formation, induces senescence⁷⁹. It is not known how senescence can be triggered both by heterochromatin disruption and by activities that are associated with heterochromatin formation. Both manipulations cause extensive but incomplete changes in chromatin organization, so each may alter the expression of different critical genes, and the response may be cell-type specific. Understanding this paradox could be important, because HDAi holds promise for treating certain cancers⁸⁰.

Oncogene-induced senescence. Oncogenes are mutant versions of normal genes that have the potential to transform cells in conjunction with additional mutations. Normal cells respond to many oncogenes by undergoing senescence. This phenomenon was first observed when an oncogenic form of RAS, a cytoplasmic transducer of mitogenic signals, was expressed in normal human fibroblasts¹⁸. Subsequently, other members of the RAS signalling pathway (for example, RAF, MEK, MOS and BRAF), as well as pro-proliferative nuclear proteins (for example, E2F-1), were shown to cause senescence when overexpressed or expressed as oncogenic versions^{22,81–83}.

Because oncogenes that induce senescence stimulate cell growth, the senescence response may counteract excessive mitogenic stimulation, which puts cells at risk of oncogenic transformation. This idea is supported by the finding that mouse cells that are cultured in serum-free medium (which reduces the high mitogenic pressure of serum) resist RAS-induced senescence⁸⁴. Likewise, some rodent cells do not replicatively senesce (BOX 1) in serum-free medium, which suggests that excessive mitogenic stimulation is responsible for their senescence^{85,86}.

Euchromatin

Chromatin that is in an open conformation and hence accessible. Also termed active chromatin.

Heterochromatin

Chromatin that is in a closed conformation and hence inaccessible. Also termed silent or inactive chromatin. Chromatin probably exists in many forms between the extremes of euchromatin and heterochromatin.




Figure 3 | The DNA-damage response. DNA damage in the form of DNA double-strand breaks and other DNA discontinuities is thought to be sensed by a host of factors such as replication protein A (RPA) and replication factor C (RFC)-like complexes (which contain the cell-cycle-checkpoint protein RAD17). These complexes recruit the 911 complex (RAD9–HUS1–RAD1). Damage is also sensed by the MRN complex (MRE11–RAD50–NBS1). Detection of DNA damage then leads to the activation of upstream protein kinases such as ataxia telangiectasia mutated (ATM) and ATM and Rad-3 related (ATR), which trigger immediate events such as phosphorylation of the histone variant H2AX. The modified chromatin recruits multiple proteins. Some of these proteins augment signalling by the upstream kinases, participate in transducing the damage signal and optimize repair activities by other proteins, the identity of which depends on the nature of the damage and position in the cell cycle (for example, the DNA end-stabilizing heterodimers Ku70/80, DNA ligases such as ligase IV, exonucleases such as MRE11, DNA helicases such as BLM). Several adaptor proteins, including MDC1, 53BP1, BRCA1 and claspin, orchestrate the orderly recruitment of DNA-damage response proteins, as well as the function of downstream kinases such as checkpoint-1 (CHK1) and CHK2, which propagate the damage signal to effector molecules such as SMC1, CDC25 and the tumour suppressor p53. The effector molecules halt cell-cycle progression, either transiently or permanently (senescence), or trigger cell death (apoptosis). 53BP1, p53-binding protein-1; BRCA1, breast cancer type-1 susceptibility protein; HUS1, hydroxyurea-sensitive-1 protein; MDC1, mediator of DNA damage checkpoint protein-1; MRE11, meiotic recombination-11 protein; NBS1, Nijmegen breakage syndrome-1 protein; SMC1, structural maintenance of chromosomes protein-1.

Is oncogene-induced senescence distinct from chromatin or telomere/damage-induced senescence? Perhaps not; for example, oncogenic RAS induces p16 and the formation of SAHFs^{45,87,88}. Moreover, although oncogene-induced senescence does not entail telomere shortening, many oncogenes induce a robust DDR owing to the DNA damage that is caused by aberrant DNA replication. This DDR has a causal role in both the initiation and maintenance of oncogene-induced senescence because its experimental downregulation prevents senescence, allows cell proliferation and predisposes cells to oncogenic transformation^{20,89}.

Oncogene-induced senescence was first identified in cultured cells and does not occur in all cells^{90,91}, so is it physiologically relevant? Recent findings show that oncogenes elicit a senescence response that curtails the development of cancer^{83,92–95}. In mice, strong mitogenic

signals that are caused by activated oncogenes, or loss of the tumour suppressor protein *PTEN* (which dampens mitogenic signals), cause benign lesions that consist of senescent cells. Likewise, benign naevi in human skin contain cells that express oncogenic BRAF and are senescent. These findings suggest that oncogene-induced senescence occurs and suppresses tumorigenesis *in vivo*. Tumorigenesis requires additional mutations — notably in p53 or p16 — that prevent or perhaps reverse the senescence growth arrest^{92,93,95}.

Stress and other inducers of senescence. Sustained signalling by certain anti-proliferative cytokines, such as interferon- β , also causes senescence. Acute interferon- β stimulation reversibly arrests cell growth, but chronic stimulation increases intracellular oxygen radicals and elicits a p53-dependent DDR and senescence⁹⁶. Likewise, chronic signalling by transforming growth factor- β , an inhibitor of epithelial cell proliferation, induces senescence by promoting p16–pRB-dependent heterochromatin formation^{97,98}.

Finally, the loosely defined phenomenon referred to as cell-culture stress, or ‘culture shock’, can induce p16-dependent, telomere-independent senescence. For example, human keratinocytes and mammary epithelial cells spontaneously express p16 and senesce with long telomeres under standard culture conditions. This does not occur when the cells are cultured on feeder layers (‘lawns’ of fibroblasts), but after many doublings on feeder layers, the cells eventually undergo telomere-dependent senescence⁹⁹. These findings suggest that, in addition to hyperphysiological growth conditions, inadequate growth conditions also induce senescence.

Some cells lack a p16-dependent senescence response because the gene encoding p16 is silenced, often by DNA methylation^{100,101}. Many human cell cultures, including fibroblasts, are heterogeneous and replicatively senesce as mosaics; some cells senesce due to the expression of p16 and others senesce due to telomere shortening and a p53-dependent DDR^{16,52,53}. The stimuli that induce p16 are poorly understood. In some cells, oxidative stress induces p16 (REFS 70,102), but this is not always the case⁵³. Oncogenic RAS can induce p16 by phosphorylating and activating ETS transcription factors⁸⁷, but expression of p16 is controlled by multiple factors, including the chromatin state^{44,77,103}.

The expression of p16 and a loss of p16 inducibility also occur *in vivo*. Expression of p16 increases with age in many murine tissues^{51,104}, and was recently shown to increase in murine haematopoietic, neuronal and pancreatic stem or progenitor cells *in vivo*^{105–107}. This expression prevents stem-cell proliferation, possibly by inducing senescence. Moreover, human mammary epithelial cells spontaneously silence p16 via promoter methylation *in vivo*¹⁰⁸ such that, as in culture, the adult breast epithelial compartment is mosaic for the expression of p16.

Control by the p53 and p16–pRB pathways

The senescence growth arrest is established and maintained by the p53 and p16–pRB tumour suppressor pathways (FIG. 4). These pathways interact but can

independently halt cell-cycle progression. To some extent, they also respond to different stimuli. In addition, there are both cell-type-specific and species-specific differences in the propensity with which cells engage one or the other pathway, and in the ability of each pathway to induce senescence. Finally, although most cells senesce owing to engagement of the p53 pathway, p16–pRB pathway, or both, there are examples of senescence that appear to be independent of these pathways^{21,83}. These examples raise the possibility of a p53- and p16–pRB-independent senescence pathway(s).

The p53 pathway. Stimuli that generate a DDR (for example, ionizing radiation and telomere dysfunction) induce senescence primarily through the p53 pathway. This pathway is regulated at multiple points by proteins such as the E3 ubiquitin-protein ligase *HDM2* (MDM2 in mice), which facilitates p53 degradation, and the alternate-reading-frame protein (ARF), which inhibits *HDM2* activity⁴². p21 is a crucial transcriptional target of p53 and mediator of p53-dependent senescence¹⁰⁹. However, p21 also mediates a transient DNA-damage-induced growth arrest. So what determines whether cells senesce or arrest transiently? The answer is currently unknown. One possibility is that rapid DNA repair quickly terminates p53–p21 signalling, whereas slow, incomplete or faulty repair results in sustained signalling and senescence. Whatever the case, experimental reduction in p53, p21 or DDR proteins (for example, ATM or CHK2) prevents telomere- or damage-induced senescence, and, in some cells (for example, those that express little or no p16 or oncogenic RAS), it can even reverse the senescence growth arrest^{20,52,55,64,109,110}. The proliferation of damaged cells with a reduced DDR or p53 function often cannot be sustained, however, because telomeres eventually become severely eroded, leading to a state of extensive genomic instability and cell death that is termed crisis or mitotic catastrophe (BOX 1). Rare mutational or epigenetic events can activate TERT expression or recombination mechanisms to elongate telomeres¹¹¹. Such cells are at a high risk of malignant transformation because they can replicate indefinitely and harbour mutations and chromosomal abnormalities.

The DDR and p53 pathway provide a first line of defence against cancer by preventing the growth of cells with severely damaged DNA, which are at risk of developing and propagating oncogenic mutations^{112,113}. However, the loss of p53 or an intact DDR — either before cells experience damage or after damage-induced senescence — usually leads to mitotic catastrophe, which acts as a second barrier that must be overcome by telomere stabilization¹¹¹.

The p16–pRB pathway. Stimuli that produce a DDR can also engage the p16–pRB pathway, but this usually occurs secondary to engagement of the p53 pathway^{71,72}. Nonetheless, some senescence-inducing stimuli act primarily through the p16–pRB pathway. This is particularly true of epithelial cells, which are more prone than fibroblasts to inducing p16 and arresting proliferation, at least in culture. Furthermore, there are species-specific differences:




Figure 4 | Senescence controlled by the p53 and p16–pRB pathways. Senescence-inducing signals, including those that trigger a DNA-damage response (DDR), as well as many other stresses (FIG. 1), usually engage either the p53 or the p16–retinoblastoma protein (pRB) tumour suppressor pathways. Some signals, such as oncogenic RAS, engage both pathways. p53 is negatively regulated by the E3 ubiquitin-protein ligase *HDM2* (MDM2 in mice), which facilitates its degradation, and *HDM2* is negatively regulated by the alternate-reading-frame protein (ARF). Active p53 establishes the senescence growth arrest in part by inducing the expression of p21, a cyclin-dependent kinase (CDK) inhibitor that, among other activities, suppresses the phosphorylation and, hence, the inactivation of pRB. Senescence signals that engage the p16–pRB pathway generally do so by inducing the expression of p16, another CDK inhibitor that prevents pRB phosphorylation and inactivation. pRB halts cell proliferation by suppressing the activity of E2F, a transcription factor that stimulates the expression of genes that are required for cell-cycle progression. E2F can also curtail proliferation by inducing ARF expression, which engages the p53 pathway. So, there is reciprocal regulation between the p53 and p16–pRB pathways. Interactions among ARF, *HDM2*, p53, p21, CDKs, pRB and E2F also occur in other cell contexts — for example, during the DDR and reversible or transient growth arrest — so it not yet clear how senescence, as opposed to quiescence or transient growth arrest, is established. It is noteworthy, however, that at least in cell-culture studies, upregulation of p16 is not part of the immediate DDR and does not occur during transient growth arrests or quiescence.

for example, experimental disruption of telomeres primarily engages the p53 pathway in mouse cells but both the p53 and p16–pRB pathways in human cells¹¹⁴.

Oncogenic RAS induces p16 expression by activating ETS transcription factors; ETS activity is counteracted by ID proteins⁸⁷, which are downregulated in senescent cells¹¹⁵. It is not clear how other senescence-causing stimuli induce p16 expression. One possible mechanism is the reduced expression of Polycomb INK4a repressors such

as BMI1 (REFS 53,116) and CBX7 (REF. 117). Consistent with this idea, BMI1 or CBX7 overexpression extends the replicative lifespan of human and mouse fibroblasts^{53,103,117}.

p16 and p21 are both CDKIs; hence, both can keep pRB in an active, hypophosphorylated form, thereby preventing E2F from transcribing genes that are needed for proliferation⁴². However, p16 and p21 are clearly not equivalent¹¹⁸. Cells that senesce solely due to p53–p21 activation can resume growth after inactivation of the p53 pathway, and do so for many cell doublings until crisis or mitotic catastrophe occurs^{20,52,55,64,110}. However, although cells that senesce due to oncogenic RAS (which induces p16 expression) can resume limited proliferation²⁰, cells that fully engage the p16–pRB pathway for several days usually cannot resume growth even after inactivation of p53, pRB or p16 (REF. 52). Moreover, the loss of p16–pRB activity upregulates p53 and p21 expression in part because E2F also stimulates ARF expression^{119,120}. Despite reciprocal regulation between the p53 and p16–pRB pathways (FIG. 4), there are differences in how cells respond when one or the other pathway mediates a senescence response.

The p16–pRB pathway is crucial for generating SAHFs, which silence the genes that are needed for proliferation⁴⁵. SAHFs require several days to develop, during which time there are transient interactions among chromatin-modifying proteins such as HIRA (histone repressor A), ASF1a (anti-silencing function-1a) and HP1 (REF. 88). Ultimately, each SAHF contains portions of a single condensed chromosome, which is depleted for the linker histone H1 and enriched for HP1 and the histone variant macroH2A^{121,122}. Like the growth arrest, once established, SAHFs no longer require p16 or pRB for maintenance⁴⁵. These findings suggest that the p16–pRB pathway can establish self-maintaining senescence-associated heterochromatin. This activity may be due to the ability of pRB to complex with histone-modifying enzymes that form repressive chromatin¹²³. Although SAHFs are not present in all senescent cells, the p16–pRB pathway might establish chromatin states that are functionally, if not cytologically, equivalent to SAHFs in cells that do not develop these structures.

Significance of senescence *in vivo*

Hayflick's observations¹ were made using cultured cells, and much of our current understanding of the causes and consequences of senescence still derives from cell cultures. Only during the past decade or so has cellular senescence been shown to occur and to be important *in vivo*.

Senescent cells *in vivo*. Senescence-associated markers (see above) have been used to identify senescent cells *in vivo*, with the caveat that none of these markers are exclusive to the senescent state. In rodents, primates and humans, senescent cells are found in many renewable tissues, including the vasculature, haematopoietic system, many epithelial organs and the stroma^{12,49,51,124}. Notably, cells that express one or more senescence markers are relatively rare in young organisms, but their number increases with age. How abundant are senescent

cells in aged organisms? Estimates vary widely depending on the study, species and tissue, ranging from <1% to >15%. It is difficult to know the cause of the senescence response from these studies. However, among the senescence markers that accumulate with age are SDFs that co-localize with telomeres, suggesting that, at least in some tissues, telomere dysfunction causes senescence *in vivo*.

Cells that express senescence markers are also found at sites of chronic age-related pathology, such as osteoarthritis and atherosclerosis^{125–127}. Thus, senescent cells are associated with ageing and age-related diseases *in vivo*, as suggested by Hayflick's early experiments. In addition, senescent cells are associated with benign dysplastic or preneoplastic lesions^{83,92–94} and benign prostatic hyperplasia¹²⁸, but not with malignant tumours. They are also found in normal and tumour tissues following DNA-damaging chemotherapy^{73–76}. These findings support the second speculation from Hayflick's experiments — that cellular senescence suppresses the development of cancer. Senescent cells are therefore found at appropriate times and places for their proposed roles in tumour suppression and ageing.

Why do senescent cells accumulate *in vivo*? The answer to this question is not known. Recent findings suggest that senescent cells, at least those induced by acute p53 activation in murine tumour models, can be cleared by host mechanisms such as the immune system^{129,130}. Virtually nothing is known about how senescent cells are recognized by the immune system, whether additional mechanisms clear them *in vivo* or whether clearance mechanisms change with age or in age-related diseases. Likewise, nothing is known about whether the senescent cells found *in vivo* have escaped clearance or are in the process of being cleared.

Cellular senescence and cancer. Senescence-inducing stimuli are potentially oncogenic, and cancer cells must acquire mutations that allow them to avoid telomere-dependent and oncogene-induced senescence^{2,93,131–133}. These mutations typically occur in the p53 and p16–pRB pathways. Of course, these pathways have multiple activities, all of which may contribute to their tumour suppressor activities. Nonetheless, there are several instances in which loss of the senescence response appears to be a crucial, albeit insufficient, step in the development of cancer. For example, genetically engineered mice that are deficient in a histone methyltransferase or p53 contain cells that fail to senesce in response to appropriate stimuli; these mice are invariably cancer-prone^{92,93,134}. Likewise, cells from patients with Li-Fraumeni syndrome, which carry mutations in p53 or CHK2 (REFS 135,136), overcome senescence much more readily than normal cells¹³⁷; humans with these mutations are also cancer-prone. Finally, as noted earlier, some preneoplastic lesions contain large numbers of cells that express senescence markers, which suggests that a senescence response halts their progression to malignancy.

Cellular senescence probably suppresses tumorigenesis because cancer development requires cell proliferation², so any mechanism that stringently prevents cell growth




Figure 5 | Potential deleterious effects of senescent cells. Damage to cells within tissues can result in several outcomes. Of course, the damage may be completely repaired, restoring the cell and tissue to its pre-damaged state. Excessive or irreparable damage, however, can cause cell death (apoptosis), senescence or an oncogenic mutation. The division of a neighbouring cell, or a stem or progenitor cell, usually replaces apoptotic cells. Cell division, however, increases the risk of fixing DNA damage as an oncogenic mutation, leaving the tissue with pre-malignant or potentially malignant cells. Senescent cells, by contrast, may not be readily replaced; in any case, their number can increase with age. Senescent cells secrete various factors that can alter or inhibit the ability of neighbouring cells to function, resulting in dysfunctional cells. They can also stimulate the proliferation and malignant progression of nearby premalignant cells. Therefore, an accumulation of senescent cells can both compromise normal tissue function and facilitate cancer progression.

will, a priori, prevent cancer. However, failure to senesce is usually insufficient for malignant transformation. This is particularly true for replicative senescence; for example, telomerase prevents telomere-initiated senescence, but does not confer malignant properties on cells¹³⁸. Likewise, the inactivation of p16, p21 or certain DDR genes — or even p53 or pRB (for example, by viral oncogenes) — increases the replicative lifespan of human cells but does not transform them *per se*^{20,109,139}. Such cells usually enter crisis, from which rare replicatively immortal cells (which have overcome the end-replication problem) can arise¹³⁹. Even then, the immortal cells may not be tumorigenic until they acquire mutations that activate mitogenic oncogenes such as RAS or inactivate tumour suppressors that dampen mitogenic signals such as PTEN^{83,92,93,140}. Thus, genetic or epigenetic events that avert replicative senescence are necessary but insufficient for malignant tumorigenesis.

Senescence reversal can occur if cells senesce without fully engaging the p16–pRB pathway and subsequently lose p53 function⁵². It is not known whether this occurs *in vivo*. However, cells with silenced (methylated) p16 exist in apparently normal tissue¹⁰⁸; should such cells senesce (for example, in response to telomere dysfunction or DNA damage) and subsequently lose p53 function, they could, in principle, resume proliferation. Likewise, senescent p16-negative cells in dysplastic naevi⁸³ could acquire a mutation that inactivates p53

function and revert to a proliferating state. Non-dividing cells can acquire mutations⁴ so these scenarios are not impossible, but it is not clear whether they are plausible. Whatever the case, it is apparent that senescence poses a formidable but not insurmountable barrier to cancer progression.

Cellular senescence and ageing. The link between cellular senescence and ageing is more tentative than the link to cancer¹². As noted earlier, the number of senescent cells increases with age, and senescent cells are present at sites of age-related pathology. Further, recent findings implicate p16-dependent senescence in three hallmarks of ageing — decrements in neurogenesis, haematopoiesis and pancreatic function^{105–107}. p16 expression increases with age in the stem and progenitor cells of the mouse brain, bone marrow and pancreas, where it suppresses stem-cell proliferation and tissue regeneration. This rise in p16-positive stem cells is apparent in early middle-age. Strikingly, the age-related decline in stem-cell growth and tissue regeneration is substantially retarded in mice that have been genetically engineered to lack p16 expression. However, as expected, these mice die prematurely (in late middle-age) of cancer.

The age-dependent rise in p16-positive stem and progenitor cells is consistent with the idea that stem-cell senescence might at least partly explain the age-related decline in brain and bone-marrow function and the development of **type II diabetes**. However, it is not yet known whether the p16-positive stem and progenitor cells are in fact senescent. So, it is possible that both the tumour-suppressive and pro-ageing activities of p16 are partly due to growth suppression without senescence. Nonetheless, these findings suggest that the tumour-suppressive activity of p16 might be inextricably linked to its pro-ageing effects. A similar trade-off between tumour suppression and ageing is seen in mice with constitutively hyperactive forms of p53 — animals that express these forms are remarkably tumour-free, but show multiple signs of accelerated ageing^{141,142}, which are at least partly due to their increased sensitivity to senescence-inducing stimuli¹⁴².

A second mechanism by which senescent cells might contribute to ageing comes from their altered pattern of gene expression — specifically, the upregulation of genes that encode extracellular-matrix-degrading enzymes, inflammatory cytokines and growth factors, which can affect the behaviour of neighbouring cells or even distal cells within tissues¹² (FIG. 5). These secreted factors can disrupt the normal tissue structure and function in cell-culture models (for example, the functional and morphological differentiation of mammary epithelial cells or epidermal keratinocytes)^{143,144}. Moreover, factors secreted by senescent cells can stimulate the growth and angiogenic activity of nearby premalignant cells, both in culture and *in vivo*^{145–149}. Therefore, senescent cells, which themselves cannot form tumours, may fuel the progression of nearby premalignant cells, thereby — ironically — facilitating the development of cancer in ageing organisms. Together, these findings support the idea that the senescence response is antagonistically

pleiotropic, and balances the benefits of suppressing cancer in young organisms against promoting the development of deleterious ageing phenotypes^{8,12}.

Future questions and directions

Despite the transition from cell-culture curiosity to potential regulator of cancer and ageing, cellular senescence remains enigmatic and continues to pose a host of questions. Precisely how do the p53 and p16–pRB pathways establish and, equally importantly, maintain the senescent growth arrest? Both of these tumour-suppressor pathways also cause transient or reversible cell-cycle arrests, so how are their activities modified by senescence-inducing signals? For that matter, how do cells ‘decide’ whether to undergo a transient growth arrest, senescence or apoptosis in response to damage or stress signals? The signals that induce p16, both in culture and *in vivo*, are especially obscure at present.

Likewise, little is known about the mechanisms that are responsible for the apparently deleterious senescent secretory phenotype. How and why does this phenotype develop? Finally, how does the senescence response balance tumour suppression, tissue regeneration and ageing phenotypes? Clearly, it would not be desirable to reverse

the senescence growth arrest — this would allow damaged, stressed or oncogene-expressing cells to proliferate and therefore increase the risk of cancer. But will it be possible to eliminate the deleterious (pro-ageing) aspects of cellular senescence (for example, the senescent secretory phenotype) without reversing the tumour-suppressive growth arrest? The generation of engineered mice that carry additional copies of properly regulated p53 (REF. 150) or p16 and ARF¹⁵¹, or have reduced activity of the negative p53 regulator MDM2 (REF. 152), lend hope to this possibility. These mice develop little cancer without signs of accelerated ageing. However, the lifespans of these mice were not significantly longer than control mice, despite cancer being a major cause of death in mice. It remains to be seen whether other, possibly non-lethal, age-related pathologies were accelerated or exacerbated. The existence of these mice also raises the possibility that there is (or can be) little or no trade-off between tumour suppression and longevity, if not between tumour suppression and ageing phenotypes or certain age-related pathologies. Whatever the case, it might be possible, through specific interventions, to ameliorate any antagonistically pleiotropic effects that tumour suppressors might have.

1. Hayflick, L. The limited *in vitro* lifetime of human diploid cell strains. *Exp. Cell Res.* **37**, 614–636 (1965).
A classic paper that describes the limited replicative lifespan of normal human cells.
2. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. *Cell* **100**, 57–70 (2000).
3. Bishop, J. M. Cancer: the rise of the genetic paradigm. *Genes Dev.* **9**, 1309–1315 (1995).
References 2 and 3 describe the characteristics of cancer cells and the importance of mutations in cancer development.
4. Busuttill, R. A., Rubio, M., Dolle, M. E., Campisi, J. & Vijg, J. Mutant frequencies and spectra depend on growth state and passage number in cells cultured from transgenic lacZ-plasmid reporter mice. *DNA Repair* **5**, 52–60 (2006).
5. Sager, R. Senescence as a mode of tumor suppression. *Environ. Health Perspect.* **93**, 59–62 (1991).
6. Campisi, J. Cellular senescence as a tumor-suppressor mechanism. *Trends Cell Biol.* **11**, 27–31 (2001).
7. Braig, M. & Schmitt, C. A. Oncogene-induced senescence: putting the brakes on tumor development. *Cancer Res.* **66**, 2881–2884 (2006).
8. Campisi, J. Cancer and ageing: rival demons? *Nature Rev. Cancer* **3**, 339–349 (2003).
9. Kirkwood, T. B. & Austad, S. N. Why do we age? *Nature* **408**, 233–238 (2000).
10. Dimri, G. P. What has senescence got to do with cancer? *Cancer Cell* **7**, 505–512 (2005).
11. Wright, W. E. & Shay, J. W. Cellular senescence as a tumor-protection mechanism: the essential role of counting. *Curr. Opin. Genet. Dev.* **11**, 98–103 (2001).
12. Campisi, J. Senescent cells, tumor suppression and organismal aging: good citizens, bad neighbors. *Cell* **120**, 513–522 (2005).
13. Hornsby, P. J. Cellular senescence and tissue aging *in vivo*. *J. Gerontol.* **57**, 251–256 (2002).
References 5–13 describe the historic and current evidence that cellular senescence suppresses the development of cancer. In addition, references 8 and 9 explain the concept of antagonistic pleiotropy.
14. Kim, W. Y. & Sharpless, N. E. The regulation of INK4/ARF in cancer and aging. *Cell* **127**, 265–275 (2006).
15. DiLeonardo, A., Linke, S. P., Clarkin, K. & Wahl, G. M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. *Genes Dev.* **8**, 2540–2551 (1994).
16. Herbig, U., Jobling, W. A., Chen, B. P., Chen, D. J. & Sedivy, J. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). *Mol. Cell* **14**, 501–513 (2004).
17. Ogryzko, V. V., Hirai, T. H., Russanova, V. R., Barbic, D. A. & Howard, B. H. Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. *Mol. Cell. Biol.* **16**, 5210–5218 (1996).
18. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* **88**, 593–602 (1997).
19. Wada, T. *et al.* MKK7 couples stress signaling to G2/M cell-cycle progression and cellular senescence. *Nature Cell Biol.* **6**, 215–226 (2004).
20. Di Micco, R. *et al.* Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. *Nature* **444**, 638–642 (2006).
21. Olsen, C. L., Gardie, B., Yaswen, P. & Stampfer, M. R. Raf-1-induced growth arrest in human mammary epithelial cells is p16-independent and is overcome in immortal cells during conversion. *Oncogene* **21**, 6328–6339 (2002).
22. Zhu, J., Woods, D., McMahon, M. & Bishop, J. M. Senescence of human fibroblasts induced by oncogenic raf. *Genes Dev.* **12**, 2997–3007 (1998).
23. Shay, J. W. & Roninson, I. B. Hallmarks of senescence in carcinogenesis and cancer therapy. *Oncogene* **23**, 2919–2933 (2004).
References 15–23 show that many potentially oncogenic stimuli can induce a senescence response.
24. Itahana, K., Campisi, J. & Dimri, G. P. Mechanisms of cellular senescence in human and mouse cells. *Biogerontology* **5**, 1–10 (2004).
25. Ellis, R. E., Yuan, J. Y. & Horvitz, H. R. Mechanisms and functions of cell death. *Annu. Rev. Cell Biol.* **7**, 663–698 (1991).
26. Green, D. R. & Evan, G. I. A matter of life and death. *Cancer Cell* **1**, 19–30 (2002).
27. Hampel, B., Malisan, F., Niederregger, H., Testi, R. & Jansen-Durr, P. Differential regulation of apoptotic cell death in senescent human cells. *Exp. Gerontol.* **39**, 1713–1721 (2004).
28. Chen, Q. M., Liu, J. & Merrett, J. B. Apoptosis or senescence-like growth arrest: influence of cell-cycle position, p53, p21 and bax in H2O2 response of normal human fibroblasts. *Biochem. J.* **347**, 543–551 (2000).
29. Tepper, C. G., Seldin, M. F. & Mudryj, M. Fas-mediated apoptosis of proliferating, transiently growth-arrested, and senescent normal human fibroblasts. *Exp. Cell Res.* **260**, 9–19 (2000).
30. Rebbaa, A., Zheng, X., Chou, P. M. & Mirkin, B. L. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. *Oncogene* **22**, 2805–2811 (2003).
31. Seluanov, A. *et al.* Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53. *Mol. Cell. Biol.* **21**, 1552–1564 (2001).
32. Crescenzi, E., Palumbo, G. & Brady, H. J. Bcl-2 activates a programme of premature senescence in human carcinoma cells. *Biochem. J.* **375**, 263–274 (2003).
33. Marcotte, R., Lacelle, C. & Wang, E. Senescent fibroblasts resist apoptosis by downregulating caspase-3. *Mech. Ageing Dev.* **125**, 777–783 (2004).
34. Murata, Y. *et al.* Death-associated protein 3 regulates cellular senescence through oxidative stress response. *FEBS Lett.* **580**, 6093–6099 (2006).
35. Jackson, J. G. & Pereira-Smith, O. M. p53 is preferentially recruited to the promoters of growth arrest genes p21 and GADD45 during replicative senescence of normal human fibroblasts. *Cancer Res.* **66**, 8356–8360 (2006).
36. Chang, B. D. *et al.* Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. *Proc. Natl Acad. Sci. USA* **99**, 389–394 (2002).
37. Mason, D. X., Jackson, T. J. & Lin, A. W. Molecular signature of oncogenic ras-induced senescence. *Oncogene* **23**, 9238–9246 (2004).
38. Shelton, D. N., Chang, E., Whittier, P. S., Choi, D. & Funk, W. D. Microarray analysis of replicative senescence. *Curr. Biol.* **9**, 939–945 (1999).
39. Trougakos, I. P., Saridakis, A., Panayotou, G. & Gonos, E. S. Identification of differentially expressed proteins in senescent human embryonic fibroblasts. *Mech. Ageing Dev.* **127**, 88–92 (2006).
40. Yoon, I. K. *et al.* Exploration of replicative senescence-associated genes in human dermal fibroblasts by cDNA microarray technology. *Exp. Gerontol.* **39**, 1369–1378 (2004).
41. Zhang, H., Pan, K. H. & Cohen, S. N. Senescence-specific gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci. *Proc. Natl Acad. Sci. USA* **100**, 3251–3256 (2003).
References 36–41 describe the many changes in gene expression that are linked to the senescence response.

42. Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. *Cancer Cell* **2**, 103–112 (2002).
43. Espinosa, J. M., Verdun, R. E. & Emerson, B. M. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. *Mol. Cell* **12**, 1015–1027 (2003).
44. Gil, J. & Peters, G. Regulation of the INK4b–ARF–INK4a tumour suppressor locus: all for one or one for all. *Nature Rev. Mol. Cell Biol.* **7**, 667–677 (2006).
45. Narita, M. *et al.* Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. *Cell* **113**, 703–716 (2003).
- The first description of senescence-associated heterochromatin foci.**
46. Pang, J. H. & Chen, K. Y. Global change of gene expression at late G1/S boundary may occur in human IMR-90 diploid fibroblasts during senescence. *J. Cell Physiol.* **160**, 531–538 (1994).
47. Seshadri, T. & Campisi, J. Repression of c-fos transcription and an altered genetic program in senescent human fibroblasts. *Science* **247**, 205–209 (1990).
48. Stein, G. H., Drullinger, L. F., Robetorye, R. S., Pereira-Smith, O. M. & Smith, J. R. Senescent cells fail to express CDC2, CYCA, and CYCB in response to mitogen stimulation. *Proc. Natl Acad. Sci. USA* **88**, 11012–11016 (1991).
49. Dimri, G. P. *et al.* A novel biomarker identifies senescent human cells in culture and in aging skin *in vivo*. *Proc. Natl Acad. Sci. USA* **92**, 9365–9367 (1995).
- First description of a senescence-associated marker that allowed the identification of senescent cells *in vivo*.**
50. Lee, B. Y. *et al.* Senescence-associated β -galactosidase is lysosomal β -galactosidase. *Aging Cell* **5**, 187–195 (2006).
51. Krishnamurthy, J. *et al.* Ink4a/Arf expression is a biomarker of aging. *J. Clin. Invest.* **114**, 1299–1307 (2004).
52. Beausejour, C. M. *et al.* Reversal of human cellular senescence: roles of the p53 and p16 pathways. *EMBO J.* **22**, 4212–4222 (2003).
53. Itahana, K. *et al.* Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. *Mol. Cell Biol.* **23**, 389–401 (2003).
54. Collado, M. & Serrano, M. The power and the promise of oncogene-induced senescence markers. *Nature Rev. Cancer* **6**, 472–476 (2006).
55. d'Adda di Fagagna, F. *et al.* A DNA damage checkpoint response in telomere-initiated senescence. *Nature* **426**, 194–198 (2003).
56. Takai, H., Smogorzewska, A. & de Lange, T. DNA damage foci at dysfunctional telomeres. *Curr. Biol.* **13**, 1549–1556 (2003).
- References 55 and 56, along with reference 16, provide the first direct evidence that dysfunctional telomeres trigger a DNA-damage response.**
57. Bartholdi, M. F. Nuclear distribution of centromeres during the cell cycle of human diploid fibroblasts. *J. Cell Sci.* **99**, 255–263 (1991).
58. Cerda, M. C., Berrios, S., Fernandez-Donoso, R., Garagna, S. & Redi, C. Organisation of complex nuclear domains in somatic mouse cells. *Biol. Cell* **91**, 55–65 (1999).
59. d'Adda di Fagagna, F., Teo, S. H. & Jackson, S. P. Functional links between telomeres and proteins of the DNA-damage response. *Genes Dev.* **18**, 1781–1799 (2004).
60. Griffith, J. D. *et al.* Mammalian telomeres end in a large duplex loop. *Cell* **97**, 503–514 (1999).
61. Harley, C. B., Futcher, A. B. & Greider, C. W. Telomeres shorten during aging of human fibroblasts. *Nature* **345**, 458–460 (1990).
- First evidence linking telomere shortening to replicative senescence.**
62. Hemann, M. T., Strong, M. A., Hao, L. Y. & Greider, C. W. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. *Cell* **107**, 67–77 (2001).
63. Martens, U. M., Chavez, E. A., Poon, S. S., Schmoor, C. & Lansdorp, P. M. Accumulation of short telomeres in human fibroblasts prior to replicative senescence. *Exp. Cell Res.* **256**, 291–299 (2000).
64. Gire, V., Roux, P., Wynford-Thomas, D., Brondello, J. M. & Dulic, V. DNA damage checkpoint kinase Chk2 triggers replicative senescence. *EMBO J.* **23**, 2554–2563 (2004).
65. Collins, K. & Mitchell, J. R. Telomerase in the human organism. *Oncogene* **21**, 564–579 (2002).
66. Effros, R. B., Dagarag, M. & Valenzuela, H. F. *In vitro* senescence of immune cells. *Exp. Gerontol.* **38**, 1243–1249 (2003).
67. Masutomi, K. *et al.* Telomerase maintains telomere structure in normal human cells. *Cell* **114**, 241–253 (2003).
68. Bodnar, A. G. *et al.* Extension of life span by introduction of telomerase into normal human cells. *Science* **279**, 349–352 (1998).
69. Chen, Q. M., Prowse, K. R., Tu, V. C., Purdom, S. & Linskens, M. H. Uncoupling the senescent phenotype from telomere shortening in hydrogen peroxide-treated fibroblasts. *Exp. Cell Res.* **265**, 294–303 (2001).
70. Parrinello, S. *et al.* Oxygen sensitivity severely limits the replicative life span of murine cells. *Nature Cell Biol.* **5**, 741–747 (2003).
71. Jacobs, J. J. & de Lange, T. Significant role for p16(INK4a) in p53-independent telomere-directed senescence. *Curr. Biol.* **14**, 2302–2308 (2004).
72. Stein, G. H., Drullinger, L. F., Soudard, A. & Dulic, V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. *Mol. Cell Biol.* **19**, 2109–2117 (1999).
73. Roninson, I. B. Tumor cell senescence in cancer treatment. *Cancer Res.* **63**, 2705–2715 (2003).
74. Roberson, R. S., Kussick, S. J., Vallieres, E., Chen, S. Y. & Wu, D. Y. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. *Cancer Res.* **65**, 2795–2803 (2005).
75. Schmitt, C. A. *et al.* A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. *Cell* **109**, 335–346 (2002).
76. te Poele, R. H., Okorokov, A. L., Jardine, L., Cummings, J. & Joel, S. P. DNA damage is able to induce senescence in tumor cells *in vitro* and *in vivo*. *Cancer Res.* **62**, 1876–1883 (2002).
- References 73–76 describe evidence that tumour cells can undergo senescence in response to DNA-damaging chemotherapy.**
77. Munro, J., Barr, N. I., Ireland, H., Morrison, V. & Parkinson, E. K. Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. *Exp. Cell Res.* **295**, 525–538 (2004).
78. Bakkenist, C. J. & Kastan, M. B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. *Nature* **421**, 499–506 (2003).
79. Bandyopadhyay, D. *et al.* Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. *Cancer Res.* **62**, 6231–6239 (2002).
80. Minucci, S. & Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. *Nature Rev. Cancer* **6**, 38–51 (2006).
81. Dimri, G. P., Itahana, K., Acosta, M. & Campisi, J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14/ARF tumor suppressor. *Mol. Cell Biol.* **20**, 273–285 (2000).
82. Lin, A. W. *et al.* Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. *Genes Dev.* **12**, 3008–3019 (1998).
83. Michaloglou, C. *et al.* BRAF^{E600}-associated senescence-like cell cycle arrest of human nevi. *Nature* **436**, 720–724 (2005).
84. Woo, R. A. & Poon, R. Y. Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation. *Genes Dev.* **18** (2004).
85. Mathon, N. F., Malcolm, D. S., Harrisingh, M. C., Cheng, L. & Lloyd, A. C. Lack of replicative senescence in normal rodent glia. *Science* **291**, 872–875 (2001).
86. Tang, D. G., Tokumoto, Y. M., Apperly, J. A., Lloyd, A. C. & Raff, M. C. Lack of replicative senescence in cultured rat oligodendrocyte precursor cells. *Science* **291**, 868–871 (2001).
87. Ohtani, N. *et al.* Opposing effects of Ets and Id proteins on p16/INK4a expression during cellular senescence. *Nature* **409**, 1067–1070 (2001).
88. Zhang, R. *et al.* Formation of macroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. *Dev. Cell* **8**, 19–31 (2005).
89. Bartkova, J. *et al.* Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. *Nature* **444**, 633–637 (2006).
90. Benanti, J. A. & Galloway, D. A. Normal human fibroblasts are resistant to RAS-induced senescence. *Mol. Cell Biol.* **24**, 2842–2852 (2004).
91. Skinner, J. *et al.* Opposing effects of mutant ras oncoprotein on human fibroblast and epithelial cell proliferation: implications for models of human tumorigenesis. *Oncogene* **23**, 5994–5999 (2004).
92. Braig, M. *et al.* Oncogene-induced senescence as an initial barrier in lymphoma development. *Nature* **436**, 660–665 (2005).
93. Chen, Z. *et al.* Critical role of p53-dependent cellular senescence in suppression of PTEN-deficient tumorigenesis. *Nature* **436**, 725–730 (2005).
94. Collado, M. *et al.* Identification of senescent cells in premalignant tumours. *Nature* **436**, 642 (2005).
95. Lazzarini Denchi, E., Attwooll, C., Pasini, D. & Helin, K. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. *Mol. Cell Biol.* **25**, 2660–2672 (2005).
- Together with references 83 and 89, references 92–95 provide evidence that cellular senescence suppresses tumorigenesis *in vivo*.**
96. Moiseeva, O., Mallette, F. A., Mukhopadhyay, U. K., Moores, A. & Ferbeyre, G. DNA damage signaling and p53-dependent senescence after prolonged β -interferon stimulation. *Mol. Biol. Cell* **17**, 1583–1592 (2006).
97. Vijayachandra, K., Lee, J. & Glick, A. B. Smad3 regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis model. *Cancer Res.* **63**, 3447–3452 (2003).
98. Zhang, H. & Cohen, S. N. Smurf2 up-regulation activates telomere-dependent senescence. *Genes Dev.* **18**, 3028–3040 (2004).
99. Ramirez, R. D. *et al.* Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. *Genes Dev.* **15**, 398–403 (2001).
100. Brenner, A. J., Stampfer, M. R. & Aldaz, C. M. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. *Oncogene* **17**, 199–205 (1998).
101. Huchtscha, L. I. *et al.* Loss of p16INK4a expression by methylation is associated with lifespan extension of human mammary epithelial cells. *Cancer Res.* **58**, 3508–3512 (1998).
102. Forsyth, N. R., Evans, A. P., Shay, J. W. & Wright, W. E. Developmental differences in the immortalization of lung fibroblasts by telomerase. *Aging Cell* **2**, 235–243 (2003).
103. Jacobs, J. J., Kieboom, K., Marino, S., DePinho, R. A. & van Lohuizen, M. The oncogene and Polycomb-group gene BMI-1 regulates cell proliferation and senescence through the INK4a locus. *Nature* **397**, 164–168 (1999).
104. Zindy, F., Quella, D. E., Roussel, M. F. & Sherr, C. J. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. *Oncogene* **15**, 203–211 (1997).
- First report that p16 expression increases during ageing.**
105. Janzen, V. *et al.* Stem cell aging modified by the cyclin-dependent kinase inhibitor, p16^{INK4a}. *Nature* **443**, 421–426 (2006).
106. Krishnamurthy, J. *et al.* p16^{INK4a} induces an age-dependent decline in islet regenerative potential. *Nature* **443**, 453–457 (2006).
107. Molofsky, A. V. *et al.* Declines in forebrain progenitor function and neurogenesis during aging are partially caused by increasing *Ink4a* expression. *Nature* **443**, 448–452 (2006).
- References 105–107 describe evidence that p16 limits stem-cell or progenitor-cell proliferation, which drives ageing phenotypes.**
108. Holst, C. R. *et al.* Methylation of p16(INK4a) promoters occurs *in vivo* in histologically normal human mammary epithelia. *Cancer Res.* **63**, 1596–1601 (2003).
109. Brown, J. P., Wei, W. & Sedivy, J. M. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. *Science* **277**, 831–834 (1997).
110. Won, J. *et al.* Small molecule-based reversible reprogramming of cellular lifespan. *Nature Chem. Biol.* **2**, 369–374 (2006).
111. Shay, J. W. & Wright, W. E. Senescence and immortalization: role of telomeres and telomerase. *Carcinogenesis* **26**, 867–874 (2005).

112. Bartkova, J. *et al.* DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature* **434**, 864–870 (2005).
 113. Gorgoulis, V. G. *et al.* Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature* **434**, 907–913 (2005).
 114. Smogorzewska, A. & de Lange, T. Different telomere damage signaling pathways in human and mouse cells. *EMBO J.* **21**, 4338–4348 (2002).
 115. Hara, E. *et al.* Id related genes encoding helix loop helix proteins are required for G1 progression and are repressed in senescent human fibroblasts. *J. Biol. Chem.* **269**, 2139–2145 (1994).
 116. Bracken, A. P. *et al.* The Polycomb group proteins bind throughout the INK4A–ARF locus and are disassociated in senescent cells. *Genes Dev.* **21**, 525–530 (2007).
 117. Gil, J., Bernard, D., Martinez, D. & Beach, D. Polycomb CBX7 has a unifying role in cellular lifespan. *Nature Cell Biol.* **6**, 62–67 (2004).
 118. Sherr, C. J. & Roberts, J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes Dev.* **13**, 1501–1512 (1999).
 119. Bates, S. *et al.* p14ARF links the tumor suppressors RB and p53. *Nature* **395**, 125–125 (1998).
 120. Zhang, J., Pickering, C. R., Holst, C. R., Gauthier, M. L. & Tlsty, T. D. p16INK4a modulates p53 in primary human mammary epithelial cells. *Cancer Res.* **66**, 10325–10331 (2006).
 121. Funayama, R., Saito, M., Tanobe, H. & Ishikawa, F. Loss of linker histone H1 in cellular senescence. *J. Cell Biol.* **175**, 869–880 (2006).
 122. Zhang, R., Chen, W. & Adams, P. D. Molecular dissection of formation of senescence-associated heterochromatin foci. *Mol. Cell Biol.* **27**, 2343–2358 (2007).
 123. Macaluso, M., Montanari, M. & Giordano, A. Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes. *Oncogene* **25**, 5263–5267 (2006).
 124. Jeyapalan, J. C., Ferreira, M., Sedivy, J. M. & Herbig, U. Accumulation of senescent cells in mitotic tissue of aging primates. *Mech. Ageing Dev.* **128**, 36–44 (2007).
 125. Chang, E. & Harley, C. B. Telomere length and replicative aging in human vascular tissues. *Proc. Natl Acad. Sci. USA* **92**, 11190–11194 (1995).
 126. Price, J. S. *et al.* The role of chondrocyte senescence in osteoarthritis. *Aging Cell* **1**, 57–65 (2002).
 127. Vasile, E., Tomita, Y., Brown, L. F., Kocher, O. & Dvorak, H. F. Differential expression of thymosin β -10 by early passage and senescent vascular endothelium is modulated by VPF/VEGF: Evidence for senescent endothelial cells *in vivo* at sites of atherosclerosis. *FASEB J.* **15**, 458–466 (2001).
 128. Castro, P., Giri, D., Lamb, D. & Ittmann, M. Cellular senescence in the pathogenesis of benign prostatic hyperplasia. *Prostate* **55**, 30–38 (2003).
 129. Ventura, A. *et al.* Restoration of p53 function leads to tumour regression *in vivo*. *Nature* **445**, 661–665 (2007).
 130. Xue, W. *et al.* Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. *Nature* **445**, 656–650 (2007).
 131. Cosme-Blanco, W. *et al.* Telomere dysfunction suppresses spontaneous tumorigenesis *in vivo* by initiating p53-dependent cellular senescence. *EMBO Rep.* **8**, 497–503 (2007).
 132. Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B. & Evan, G. I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. *Nature* **443**, 214–217 (2006).
 133. Feldser, D. M. & Greider, C. W. Short telomeres limit tumor progression *in vivo* by inducing senescence. *Cancer Cell* **11**, 461–469 (2007).
 134. Donehower, L. A. *et al.* Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. *Nature* **356**, 215–221 (1992).
 135. Iwakuma, T., Lozano, G. & Flores, E. R. Li-Fraumeni syndrome: a p53 family affair. *Cell Cycle* **4**, 865–867 (2005).
 136. Lee, S. B. *et al.* Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. *Cancer Res.* **61**, 8062–8067 (2001).
 137. Shay, J. W., Tomlinson, G., Piatyszek, M. A. & Gollahan, L. S. Spontaneous *in vitro* immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome. *Mol. Cell Biol.* **15**, 425–432 (1995).
 138. Morales, C. P. *et al.* Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. *Nature Genet.* **21**, 115–118 (1999).
 139. Shay, J. W., Van Der Haegen, B. A., Ying, Y. & Wright, W. E. The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen. *Exp. Cell Res.* **209**, 45–52 (1993).
 140. Hahn, W. C. *et al.* Creation of human tumor cells with defined genetic elements. *Nature* **400**, 464–468 (1999).
 141. Tyner, S. D. *et al.* p53 mutant mice that display early aging-associated phenotypes. *Nature* **415**, 45–53 (2002).
 142. Maier, B. *et al.* Modulation of mammalian life span by the short isoform of p53. *Genes Dev.* **18**, 306–319 (2004).
- References 141 and 142 show that constitutive p53 activity can suppress the development of cancer at the cost of accelerating ageing phenotypes.**
143. Funk, W. D. *et al.* Telomerase expression restores dermal integrity to *in vitro* aged fibroblasts in a reconstituted skin model. *Exp. Cell Res.* **258**, 270–278 (2000).
 144. Parrinello, S., Coppe, J. P., Krtolica, A. & Campisi, J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. *J. Cell Sci.* **118**, 485–496 (2005).
 145. Bavik, C. *et al.* The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. *Cancer Res.* **66**, 794–802 (2006).
 146. Coppe, J. P., Kauser, K., Campisi, J. & Beausejour, C. M. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. *J. Biol. Chem.* **281**, 29568–29574 (2006).
 147. Dilley, T. K., Bowden, G. T. & Chen, Q. M. Novel mechanisms of sublethal oxidant toxicity: induction of premature senescence in human fibroblasts confers tumor promoter activity. *Exp. Cell Res.* **290**, 38–48 (2003).
 148. Krtolica, A., Parrinello, S., Lockett, S., Desprez, P. & Campisi, J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. *Proc. Natl Acad. Sci. USA* **98**, 12072–12077 (2001).
 149. Martens, J. W. *et al.* Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression. *Thromb. Haemost.* **89**, 393–404 (2003).
 150. Garcia-Cao, I. *et al.* 'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally. *EMBO J.* **21**, 6225–6235 (2002).
 151. Matheu, A. *et al.* Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging. *Genes Dev.* **18**, 2736–2746 (2004).
 152. Mendrysa, S. M. *et al.* Tumor suppression and normal aging in mice with constitutively high p53 activity. *Genes Dev.* **20**, 16–21 (2006).
- References 150–152 show that resistance to cancer need not accelerate ageing.**
153. Shay, J. W., Wright, W. E. & Werbin, H. Defining the molecular mechanisms of human cell immortalization. *Biochim. Biophys. Acta Rev. Cancer* **1071**, 1–7 (1991).
 154. Romanov, S. R. *et al.* Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. *Nature* **409**, 633–637 (2001).
 155. Emsley, J. G., Mitchell, B. D., Kempermann, G. & Macklis, J. D. Adult neurogenesis and repair of the adult CNS with neural progenitors, precursors, and stem cells. *Prog. Neurobiol.* **75**, 321–341 (2005).
 156. Shi, X. & Garry, D. J. Muscle stem cells in development, regeneration, and disease. *Genes Dev.* **20**, 1692–1708 (2006).
 157. Srivastava, D. & Ivey, K. N. Potential of stem-cell-based therapies for heart disease. *Nature* **441**, 1097–1099 (2006).

Acknowledgements

The authors thank colleagues and the members of their laboratories for stimulating discussions. The F.d'A.d.F. group is supported by the Associazione Italiana per la Ricerca sul Cancro, the Association for International Cancer Research and the Human Frontier Science Program. The J.C. group is supported by the US National Institute of Aging, the National Cancer Institute and the Department of Energy.

Competing interests statement

The authors declare no competing financial interests.

DATABASES

OMIM: <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM>
 Li-Fraumeni syndrome | type II diabetes
 UniProtKB: <http://ca.expasy.org/sprot>
 ATM | CHK2 | E2F | HDM2 | p16 | p21 | p53 | pRB | PTEN

FURTHER INFORMATION

Judith Campisi's homepages:
http://www.buckinstitute.org/site/index.php?option=com_content&task=view&id=113&Itemid=100
http://www.lbl.gov/lifesciences/labs/campisi_lab.html
 Fabrizio d'Adda di Fagnaga's homepage:
<http://www.ifom-ico-campus.it/research/dadda.php>
ALL LINKS ARE ACTIVE IN THE ONLINE PDF.